Search
Research
Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhoodChildren who were born with reduced gestational age, birthweight, and birth length have persistently increased rates of infection-related admissions to hospital until age 18 years
Research
Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western AustraliaBronchiolitis hospitalisations are a reasonable proxy for the timing of RSV detections, but may not fully capture the magnitude of RSV epidemics
Research
Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal peopleAustralian Aboriginal people have among the highest rates of invasive pneumococcal disease (IPD) worldwide. This paper investigates clinical diagnosis, risk...
Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.
Research
The STAMP RSV ProgramSTAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.
Research
Validity of using a semi-automated screening tool in a systematic review assessing non-specific effects of respiratory vaccinesThe abstract screening process of systematic reviews can take thousands of hours by two researchers. We aim to determine the reliability and validity of Research Screener, a semi-automated abstract screening tool within a systematic review on non-specific and broader effects of respiratory vaccines on acute lower respiratory infection hospitalisations and antimicrobial prescribing patterns in young children.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
“It’s all gone quiet…” MUSIC from COVID19Hannah Huong Christopher Moore Le Blyth OAM BSc (Hons) GradDipClinEpi PhD MA (Dev. Econ), MA (App. Stats), PhD (Econ) MBBS (Hons) DCH FRACP FRCPA PhD
Research
Childhood pneumonia in the Eastern Highlands Province of Papua New Guinea: clinical, microbiological and immunological predictors of diseaseChristopher Deborah Hannah Lea-Ann Peter Blyth Lehmann Moore Kirkham Richmond MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc OAM BSc (Hons)
Research
Infection Transmission in Early Childhood Education and Care: a mixed methods study to inform future interventionsThe COVID-19 pandemic has exposed many uncertainties and incorrect assumptions about respiratory pathogen transmission.